The Real Story Isn’t the Pomegranate, It’s Your Gut Bacteria
Pomegranates, berries, and walnuts have been marketed as healthy-aging foods for years now, but the real story is a bit more complicated than the marketing copy suggests. The compounds actually being studied in these foods are called ellagitannins, and the problem is, your body can’t absorb them directly. Before it can do anything useful, it has to go on a journey: eaten, broken down, and reassembled by bacteria in your gut, eventually becoming a small molecule called Urolithin A.
In other words, the same pomegranate, eaten by two different people, can produce completely different results. What matters isn’t how much you eat, it’s which bacteria happen to live in your gut.
A Chemical Relay Race
Turning ellagic acid into Urolithin A takes several steps: an ester bond is opened, a carboxyl group is removed to produce an intermediate called Urolithin M5, and then hydroxyl groups are stripped away one by one, five, four, three, until only two remain and the molecule finally becomes Urolithin A. The whole pathway depends on a relay of specific gut bacteria, including Lactobacillus plantarum, Streptococcus thermophilus, and Akkermansia muciniphila. If any one of them is missing, the reaction stalls partway through.
What’s Actually Exciting Is Mitophagy
Scientific interest in Urolithin A over the past few years comes down largely to one thing: mitophagy.
Mitochondria are the power plants inside your cells, and as you age, these power plants gradually wear down and malfunction. Under normal circumstances, cells have a mechanism for clearing out damaged mitochondria, and that mechanism is called mitophagy. The problem is, this clearance system also declines with age, so damaged mitochondria pile up and cells become increasingly sluggish.
A 2016 study published in Nature Medicine found that Urolithin A induced the clearance of damaged mitochondria in C. elegans more effectively than other similar molecules, and the worms lived longer as a result. In a follow-up in vitro study on chondrocytes, researchers observed a similar effect: Urolithin A helped chondrocytes restore their mitophagy capacity, making the cells more resistant to damage under mechanical stress.
How Far Has the Research Gotten?
Let’s be upfront about something: most of the findings above come from preclinical research, in vitro and animal study data in worms, mice, and rats. There isn’t large-scale human data yet.
The good news is that Urolithin A’s safety in humans has already been studied. A 2019 randomized double-blind human trial published in Nature Metabolism found that Urolithin A had a favorable safety and bioavailability profile, along with positive shifts in biomarkers such as plasma acylcarnitines and skeletal muscle mitochondrial gene expression. Whether these shifts will eventually translate into health benefits people can actually see and feel is something researchers are still working to find out, and it’s what makes this area of research so promising.